Stockreport

Acceleron Receives FDA Breakthrough Therapy Designation for Sotatercept in Pulmonary Arterial Hypertension

Acceleron Pharma Inc.  (XLRN) 
Last acceleron pharma inc. earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.acceleronpharma.com/investor-relations
PDF Sotatercept granted first FDA Breakthrough Therapy designation in pulmonary arterial hypertension since the Agency established the designation in 2012 CAMBRIDGE, Mass [Read more]